BioWorld Asia

Feb. 20, 2002

Microscience Completes £25.5M Round, Plans Clinical Programs

LONDON - Microscience Ltd. raised £25.5 million (US$36.3 million) in a third-round funding, enabling it to put five infectious disease vaccines into clinical trials this year and develop them through to Phase IIb. (BioWorld International) Read More

Hungarian Firm ComGenex Adds Discovery To Chemistry Services

Common Gene Links Immune System’s Generation Of Diversity

British Biotech Gains License To Cancer Drug In Phase II

Alizyme Receives Approval For Phase III Trial Of Colal-Pred

LION Streamlining Operations, Eliminating About 80 Positions

EU Commissioner Continues Push For Changes In Policy

HiberGen Raises EUR3.8M In Follow-On Funding From Trinity

Other News To Note

Oxagen, Insmed Enter Alliance On Polycystic Ovary Syndrome

Arrow Raises £7M In Second Round For Anti-Infectives Work

Australian Researchers Isolate Gene Implicated In Hay Fever

Sanofi-Synthélabo Selects Melanoma Vaccine From IDM

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...